Basis: Latest stored market observation. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 0.02x is in line with its 1-year average of 0.02x, near the high end of its 1-year range (0.01x–0.02x).
As of Friday, August 28, 2026.
EV/EBITDA RATIO
0.02x
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
16.82x
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-99.88%
vs the sector median at left
PDS Biotechnology Corporation
Market Cap
$11.79M
EV/EBITDA Ratio
0.02x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.18B
EV/EBITDA Ratio
14.10x
TTM Avg
33.42x
3Y Avg
215.66x
5Y Avg
215.66x
Market Cap
$2.23B
EV/EBITDA Ratio
5.04x
TTM Avg
7.35x
3Y Avg
38.16x
5Y Avg
28.09x
Market Cap
$3.06B
EV/EBITDA Ratio
33.85x
TTM Avg
37.36x
3Y Avg
88.30x
5Y Avg
88.30x
Market Cap
$5.40B
EV/EBITDA Ratio
17.20x
TTM Avg
16.21x
3Y Avg
20.08x
5Y Avg
22.02x
Market Cap
$6.43B
EV/EBITDA Ratio
81.70x
TTM Avg
64.87x
3Y Avg
314.75x
5Y Avg
314.75x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PDS Biotechnology Corporation (PDSB) | $11.79M | 0.02x | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $438.82M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $492.43M | 24.29x | 15.25x | 15.05x | 16.67x |
| Teladoc Health, Inc. (TDOC)vs › | $1.18B | 14.10x | 33.42x | 215.66x | 215.66x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.23B | 5.04x | 7.35x | 38.16x | 28.09x |
| TransMedics Group, Inc. (TMDX)vs › | $3.06B | 33.85x | 37.36x | 88.30x | 88.30x |
| Doximity, Inc. (DOCS)vs › | $5.00B | 22.90x | 29.64x | 37.41x | 55.74x |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.40B | 17.20x | 16.21x | 20.08x | 22.02x |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.43B | 81.70x | 64.87x | 314.75x | 314.75x |
| Chemed Corporation (CHE)vs › | $6.84B | 17.60x | 15.53x | 18.91x | 18.88x |
At 0.0, EV/EBITDA is above its 1-year median — higher than 100% of readings in its 1-year history.
1-year low
0.0
median
0.0
1-year high
0.0
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-08-28 | 0.02x |
| 2026-08-27 | 0.02x |
| 2026-08-26 | 0.02x |
| 2026-08-25 | 0.02x |
| 2026-08-24 | 0.02x |
| 2026-08-21 | 0.02x |
| 2026-08-20 | 0.02x |
| 2026-08-19 | 0.01x |
| 2026-08-18 | 0.02x |
| 2026-08-17 | 0.02x |
| 2026-08-14 | 0.02x |
| 2026-08-13 | 0.02x |
